Table 3. ROC analysis of T1-derived and FT-derived biomarkers for discrimination between patients with severe AS with preserved LVEF and controls.
| Biomarkers | AUC (95% CI) | Discrimination threshold | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|
| Native T1, ms | 0.68 (0.53–0.81) | >1,298.4 | 55.2 | 85.0 |
| Post T1, ms | 0.71 (0.57–0.83) | ≤566.7 | 72.4 | 70.0 |
| λ | 0.55 (0.40–0.69) | ≤0.41 | 24.1 | 95.0 |
| ECV, % | 0.64 (0.49–0.77) | >26.6 | 69.0 | 65.0 |
| GLS, % | 0.83 (0.70–0.92) | >−19.9 | 72.4 | 85.0 |
| GCS, % | 0.82 (0.69–0.92) | >−21.5 | 65.5 | 90.0 |
| GRS, % | 0.71 (0.56–0.83) | ≤92.7 | 69.0 | 65.0 |
| GLS rate | 0.79 (0.65–0.90) | >−0.9 | 79.3 | 75.0 |
| GCS rate | 0.62 (0.47–0.76) | >−0.97 | 65.5 | 60.0 |
| GRS rate | 0.53 (0.39–0.68) | ≤1.6 | 44.8 | 80.0 |
LVEF, left ventricular ejection fraction; ROC, receive operating curve; AUC area under the curve; ECV, extracellular volume; GLS, global longitudinal strain; GCS, global circumferential strain; GRS, global radial strain.